Skip to main content
Erschienen in: International Urology and Nephrology 12/2019

27.08.2019 | Urology - Original Paper

Systemic immune-inflammation index, serum albumin, and fibrinogen impact prognosis in castration-resistant prostate cancer patients treated with first-line docetaxel

verfasst von: Ya-nan Man, Yan-fang Chen

Erschienen in: International Urology and Nephrology | Ausgabe 12/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the prognostic value of pretreatment plasma systemic immune-inflammation index (SII), albumin, and fibrinogen levels in metastatic castration-resistant prostate cancer (mCRPC) patients treated with first-line docetaxel and to screen out the patients with the greatest risk for poor prognosis.

Methods

The plasma SII, albumin, and fibrinogen levels were examined before treatment and analyzed with patient clinicopathological parameters and overall survival (OS). The survival analysis was performed using the Kaplan–Meier method, and prognostic factors were assessed using the Cox proportional hazard regression model.

Results

The incidences of elevated SII level, hypoproteinemia, and hyperfibrinogenemia were 52.51%, 25.14%, and 27.93%, respectively. SII level was associated with neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) (P < 0.001). Albumin level was found closely correlated with ECOG PS (P = 0.006), PLR (P = 0.042), and hemoglobin (P = 0.009), but not other parameters. Elevated plasma fibrinogen level was significantly associated with Eastern Cooperative Oncology Group performance status (ECOG PS) (P = 0.009), visceral metastases (P < 0.001), and PLR (P = 0.001). In multivariate Cox regression model, visceral metastases SII (HR 2.133, 95% CI 1.163–3.913; P = 0.014), albumin (HR 0.540, 95% CI 0.307–0.949; P = 0.032), and fibrinogen (HR 1.888, 95% CI 1.069–3.335; P = 0.029) were further confirmed to be the independent prognostic factors for OS. Of the three target parameters, we found that patients with none abnormalities of the three parameters showed the best prognosis, and patients with at least any two abnormalities of them showed markedly worse prognosis than patients with any one abnormalities of the three parameters (P < 0.001).

Conclusions

Pretreatment SII, albumin, and fibrinogen are independent prognostic factors in mCRPC patients treated with first-line docetaxel. Moreover, the combined use of SII, albumin, and fibrinogen levels may help us to identify the high-risk populations for treatment decisions.
Literatur
1.
3.
Zurück zum Zitat Katzenwadel A, Wolf P (2015) Androgen deprivation of prostate cancer: leading to a therapeutic dead end. Cancer Lett 367(1):12–17PubMedCrossRef Katzenwadel A, Wolf P (2015) Androgen deprivation of prostate cancer: leading to a therapeutic dead end. Cancer Lett 367(1):12–17PubMedCrossRef
4.
Zurück zum Zitat Tucci M, Scagliotti GV, Vignani F (2015) Metastatic castration-resistant prostate cancer: time for innovation. Future Oncol (Lond, Engl) 11(1):91–106CrossRef Tucci M, Scagliotti GV, Vignani F (2015) Metastatic castration-resistant prostate cancer: time for innovation. Future Oncol (Lond, Engl) 11(1):91–106CrossRef
5.
6.
Zurück zum Zitat Ryan CJ, Smith MR, Fizazi K et al (2015) Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16(2):152–160PubMedCrossRef Ryan CJ, Smith MR, Fizazi K et al (2015) Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16(2):152–160PubMedCrossRef
7.
Zurück zum Zitat de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet (Lond Engl) 376(9747):1147–1154CrossRef de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet (Lond Engl) 376(9747):1147–1154CrossRef
8.
Zurück zum Zitat Parker C, Nilsson S, Heinrich D et al (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369(3):213–223PubMedCrossRef Parker C, Nilsson S, Heinrich D et al (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369(3):213–223PubMedCrossRef
9.
Zurück zum Zitat Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363(5):411–422PubMedCrossRef Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363(5):411–422PubMedCrossRef
10.
Zurück zum Zitat Mantovani A, Allavena P, Sica A et al (2008) Cancer-related inflammation. Nature 454(7203):436–444PubMedCrossRef Mantovani A, Allavena P, Sica A et al (2008) Cancer-related inflammation. Nature 454(7203):436–444PubMedCrossRef
11.
Zurück zum Zitat Zou W (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5(4):263–274PubMedCrossRef Zou W (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5(4):263–274PubMedCrossRef
12.
Zurück zum Zitat Templeton AJ, McNamara MG, Seruga B et al (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 106(6):dju124PubMedCrossRef Templeton AJ, McNamara MG, Seruga B et al (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 106(6):dju124PubMedCrossRef
13.
Zurück zum Zitat Cannon NA, Meyer J, Iyengar P et al (2015) Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer. J Thorac Oncol 10(2):280–285PubMedCrossRef Cannon NA, Meyer J, Iyengar P et al (2015) Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer. J Thorac Oncol 10(2):280–285PubMedCrossRef
14.
Zurück zum Zitat Rossi L, Santoni M, Crabb SJ et al (2015) High neutrophil-to-lymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer. Ann Surg Oncol 22(4):1377–1384PubMedCrossRef Rossi L, Santoni M, Crabb SJ et al (2015) High neutrophil-to-lymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer. Ann Surg Oncol 22(4):1377–1384PubMedCrossRef
15.
Zurück zum Zitat Buttigliero C, Pisano C, Tucci M et al (2017) Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel. Acta Oncol 56(4):555–562PubMedCrossRef Buttigliero C, Pisano C, Tucci M et al (2017) Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel. Acta Oncol 56(4):555–562PubMedCrossRef
16.
Zurück zum Zitat Uemura K, Kawahara T, Yamashita D et al (2017) Neutrophil-to-lymphocyte ratio predicts prognosis in castration-resistant prostate cancer patients who received cabazitaxel chemotherapy. Biomed Res Int 2017:7538647PubMedPubMedCentralCrossRef Uemura K, Kawahara T, Yamashita D et al (2017) Neutrophil-to-lymphocyte ratio predicts prognosis in castration-resistant prostate cancer patients who received cabazitaxel chemotherapy. Biomed Res Int 2017:7538647PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Leibowitz-Amit R, Templeton AJ, Omlin A et al (2014) Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. Ann Oncol 25(3):657–662PubMedPubMedCentralCrossRef Leibowitz-Amit R, Templeton AJ, Omlin A et al (2014) Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. Ann Oncol 25(3):657–662PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat Conteduca V, Crabb SJ, Jones RJ et al (2016) Persistent neutrophil to lymphocyte ratio > 3 during treatment with enzalutamide and clinical outcome in patients with castration-resistant prostate cancer. PLoS One 11(7):e0158952PubMedPubMedCentralCrossRef Conteduca V, Crabb SJ, Jones RJ et al (2016) Persistent neutrophil to lymphocyte ratio > 3 during treatment with enzalutamide and clinical outcome in patients with castration-resistant prostate cancer. PLoS One 11(7):e0158952PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Hu B, Yang XR, Xu Y et al (2014) Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res 20(23):6212–6222PubMedCrossRef Hu B, Yang XR, Xu Y et al (2014) Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res 20(23):6212–6222PubMedCrossRef
20.
Zurück zum Zitat Lolli C, Basso U, Derosa L et al (2016) Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Oncotarget 7(34):54564–54571PubMedPubMedCentralCrossRef Lolli C, Basso U, Derosa L et al (2016) Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Oncotarget 7(34):54564–54571PubMedPubMedCentralCrossRef
21.
Zurück zum Zitat Passardi A, Scarpi E, Cavanna L et al (2016) Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer. Oncotarget 7(22):33210–33219PubMedPubMedCentralCrossRef Passardi A, Scarpi E, Cavanna L et al (2016) Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer. Oncotarget 7(22):33210–33219PubMedPubMedCentralCrossRef
22.
23.
Zurück zum Zitat Lolli C, Caffo O, Scarpi E et al (2016) Systemic immune-inflammation index predicts the clinical outcome in patients with mCRPC treated with abiraterone. Front Pharmacol 7:376PubMedPubMedCentralCrossRef Lolli C, Caffo O, Scarpi E et al (2016) Systemic immune-inflammation index predicts the clinical outcome in patients with mCRPC treated with abiraterone. Front Pharmacol 7:376PubMedPubMedCentralCrossRef
24.
Zurück zum Zitat Morgan TM, Tang D, Stratton KL et al (2011) Preoperative nutritional status is an important predictor of survival in patients undergoing surgery for renal cell carcinoma. Eur Urol 59(6):923–928PubMedPubMedCentralCrossRef Morgan TM, Tang D, Stratton KL et al (2011) Preoperative nutritional status is an important predictor of survival in patients undergoing surgery for renal cell carcinoma. Eur Urol 59(6):923–928PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat Chandra RK, Kumari S (1994) Nutrition and immunity: an overview. J Nutr 124(8 Suppl):1433s–1435sPubMedCrossRef Chandra RK, Kumari S (1994) Nutrition and immunity: an overview. J Nutr 124(8 Suppl):1433s–1435sPubMedCrossRef
26.
Zurück zum Zitat Marcos A, Nova E, Montero A (2003) Changes in the immune system are conditioned by nutrition. Eur J Clin Nutr 57(Suppl 1):S66–S69PubMedCrossRef Marcos A, Nova E, Montero A (2003) Changes in the immune system are conditioned by nutrition. Eur J Clin Nutr 57(Suppl 1):S66–S69PubMedCrossRef
27.
Zurück zum Zitat Gao Y, Zhou S, Jiang W et al (2003) Effects of ganopoly (a Ganoderma lucidum polysaccharide extract) on the immune functions in advanced-stage cancer patients. Immunol Invest 32(3):201–215PubMedCrossRef Gao Y, Zhou S, Jiang W et al (2003) Effects of ganopoly (a Ganoderma lucidum polysaccharide extract) on the immune functions in advanced-stage cancer patients. Immunol Invest 32(3):201–215PubMedCrossRef
28.
Zurück zum Zitat Rivadeneira DE, Grobmyer SR, Naama HA et al (2001) Malnutrition-induced macrophage apoptosis. Surgery 129(5):617–625PubMedCrossRef Rivadeneira DE, Grobmyer SR, Naama HA et al (2001) Malnutrition-induced macrophage apoptosis. Surgery 129(5):617–625PubMedCrossRef
29.
Zurück zum Zitat Reynolds JV, Redmond HP, Ueno N et al (1992) Impairment of macrophage activation and granuloma formation by protein deprivation in mice. Cell Immunol 139(2):493–504PubMedCrossRef Reynolds JV, Redmond HP, Ueno N et al (1992) Impairment of macrophage activation and granuloma formation by protein deprivation in mice. Cell Immunol 139(2):493–504PubMedCrossRef
30.
Zurück zum Zitat Cai W, Kong W, Dong B et al (2017) Pretreatment serum prealbumin as an independent prognostic indicator in patients with metastatic renal cell carcinoma using tyrosine kinase inhibitors as first-line target therapy. Clin Genitourin Cancer 15(3):e437–e446PubMedCrossRef Cai W, Kong W, Dong B et al (2017) Pretreatment serum prealbumin as an independent prognostic indicator in patients with metastatic renal cell carcinoma using tyrosine kinase inhibitors as first-line target therapy. Clin Genitourin Cancer 15(3):e437–e446PubMedCrossRef
31.
Zurück zum Zitat Kawai H, Ota H (2012) Low perioperative serum prealbumin predicts early recurrence after curative pulmonary resection for non-small-cell lung cancer. World J Surg 36(12):2853–2857PubMedCrossRef Kawai H, Ota H (2012) Low perioperative serum prealbumin predicts early recurrence after curative pulmonary resection for non-small-cell lung cancer. World J Surg 36(12):2853–2857PubMedCrossRef
32.
Zurück zum Zitat Kelly P, Paulin F, Lamont D et al (2012) Pre-treatment plasma proteomic markers associated with survival in oesophageal cancer. Br J Cancer 106(5):955–961PubMedPubMedCentralCrossRef Kelly P, Paulin F, Lamont D et al (2012) Pre-treatment plasma proteomic markers associated with survival in oesophageal cancer. Br J Cancer 106(5):955–961PubMedPubMedCentralCrossRef
33.
Zurück zum Zitat Fan L, Chi C, Guo S et al (2017) Serum pre-albumin predicts the clinical outcome in metastatic castration-resistant prostate cancer patients treated with abiraterone. J Cancer 8(17):3448–3455PubMedPubMedCentralCrossRef Fan L, Chi C, Guo S et al (2017) Serum pre-albumin predicts the clinical outcome in metastatic castration-resistant prostate cancer patients treated with abiraterone. J Cancer 8(17):3448–3455PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat Beer JH, Haeberli A, Vogt A et al (2002) Coagulation markers predict survival in cancer patients. Thromb Haemost 88(5):745–749PubMed Beer JH, Haeberli A, Vogt A et al (2002) Coagulation markers predict survival in cancer patients. Thromb Haemost 88(5):745–749PubMed
35.
Zurück zum Zitat Koh SC, Tham KF, Razvi K et al (2001) Hemostatic and fibrinolytic status in patients with ovarian cancer and benign ovarian cysts: could d-dimer and antithrombin III levels be included as prognostic markers for survival outcome? Clin Appl Thromb Hemost 7(2):141–148PubMedCrossRef Koh SC, Tham KF, Razvi K et al (2001) Hemostatic and fibrinolytic status in patients with ovarian cancer and benign ovarian cysts: could d-dimer and antithrombin III levels be included as prognostic markers for survival outcome? Clin Appl Thromb Hemost 7(2):141–148PubMedCrossRef
36.
Zurück zum Zitat Pichler M, Dalpiaz O, Ehrlich GC et al (2014) Validation of the preoperative plasma fibrinogen level as a prognostic factor in a European cohort of patients with localized upper tract urothelial carcinoma. J Urol 191(4):920–925PubMedCrossRef Pichler M, Dalpiaz O, Ehrlich GC et al (2014) Validation of the preoperative plasma fibrinogen level as a prognostic factor in a European cohort of patients with localized upper tract urothelial carcinoma. J Urol 191(4):920–925PubMedCrossRef
37.
Zurück zum Zitat Seebacher V, Polterauer S, Grimm C et al (2010) The prognostic value of plasma fibrinogen levels in patients with endometrial cancer: a multi-centre trial. Br J Cancer 102(6):952–956PubMedPubMedCentralCrossRef Seebacher V, Polterauer S, Grimm C et al (2010) The prognostic value of plasma fibrinogen levels in patients with endometrial cancer: a multi-centre trial. Br J Cancer 102(6):952–956PubMedPubMedCentralCrossRef
38.
Zurück zum Zitat Ay C, Vormittag R, Dunkler D et al (2009) D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 27(25):4124–4129PubMedCrossRef Ay C, Vormittag R, Dunkler D et al (2009) D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 27(25):4124–4129PubMedCrossRef
39.
Zurück zum Zitat Wang Y, Yin W, Wang Z et al (2016) Pretreatment plasma fibrinogen as an independent prognostic indicator of prostate cancer patients treated with androgen deprivation therapy. Prostate Cancer Prostatic Dis 19(2):209–215PubMedCrossRef Wang Y, Yin W, Wang Z et al (2016) Pretreatment plasma fibrinogen as an independent prognostic indicator of prostate cancer patients treated with androgen deprivation therapy. Prostate Cancer Prostatic Dis 19(2):209–215PubMedCrossRef
40.
Zurück zum Zitat Yamashita H, Kitayama J, Kanno N et al (2006) Hyperfibrinogenemia is associated with lymphatic as well as hematogenous metastasis and worse clinical outcome in T2 gastric cancer. BMC Cancer 6:147PubMedPubMedCentralCrossRef Yamashita H, Kitayama J, Kanno N et al (2006) Hyperfibrinogenemia is associated with lymphatic as well as hematogenous metastasis and worse clinical outcome in T2 gastric cancer. BMC Cancer 6:147PubMedPubMedCentralCrossRef
41.
Zurück zum Zitat Paramanathan A, Saxena A, Morris DL (2014) A systematic review and meta-analysis on the impact of pre-operative neutrophil lymphocyte ratio on long term outcomes after curative intent resection of solid tumours. Surg Oncol 23:31–39PubMedCrossRef Paramanathan A, Saxena A, Morris DL (2014) A systematic review and meta-analysis on the impact of pre-operative neutrophil lymphocyte ratio on long term outcomes after curative intent resection of solid tumours. Surg Oncol 23:31–39PubMedCrossRef
42.
Zurück zum Zitat Pinato DJ, Stavraka C, Flynn MJ et al (2014) An inflammation based score can optimize the selection of patients with advanced cancer considered for early phase clinical trials. PLoS One 9:e83279PubMedPubMedCentralCrossRef Pinato DJ, Stavraka C, Flynn MJ et al (2014) An inflammation based score can optimize the selection of patients with advanced cancer considered for early phase clinical trials. PLoS One 9:e83279PubMedPubMedCentralCrossRef
44.
Zurück zum Zitat Labelle M, Begum S, Hynes RO (2011) Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 20:576–590PubMedPubMedCentralCrossRef Labelle M, Begum S, Hynes RO (2011) Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 20:576–590PubMedPubMedCentralCrossRef
45.
Zurück zum Zitat Liang W, Ferrara N (2016) The complex role of neutrophils in tumor angiogenesis and metastasis. Cancer Immunol Res 4:83–91PubMedCrossRef Liang W, Ferrara N (2016) The complex role of neutrophils in tumor angiogenesis and metastasis. Cancer Immunol Res 4:83–91PubMedCrossRef
46.
Zurück zum Zitat Mantovani A, Cassatella MA, Costantini C et al (2011) Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol 11:519–531PubMedCrossRef Mantovani A, Cassatella MA, Costantini C et al (2011) Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol 11:519–531PubMedCrossRef
47.
Zurück zum Zitat Mantovani A, Allavena P, Sica A et al (2011) Cancer-related inflammation. Nature 454:436–444CrossRef Mantovani A, Allavena P, Sica A et al (2011) Cancer-related inflammation. Nature 454:436–444CrossRef
48.
Zurück zum Zitat Valenzuela-Landaeta K, Rojas P, Basfi-fer K et al (2012) Nutritional assessment for cancer patient. Nutr Hosp 27(2):516–523PubMed Valenzuela-Landaeta K, Rojas P, Basfi-fer K et al (2012) Nutritional assessment for cancer patient. Nutr Hosp 27(2):516–523PubMed
49.
Zurück zum Zitat Yamashita S, Kohjimoto Y, Iguchi T et al (2016) Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy. BMC Urol 16:13PubMedPubMedCentralCrossRef Yamashita S, Kohjimoto Y, Iguchi T et al (2016) Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy. BMC Urol 16:13PubMedPubMedCentralCrossRef
50.
Zurück zum Zitat Yamashita H, Kitayama J, Kanno N et al (2006) Hyper fibrinogenemia is associated with lymphatic as well as hematogenous metastasis and worse clinical outcome in T2 gastric cancer. BMC Cancer 6:147PubMedPubMedCentralCrossRef Yamashita H, Kitayama J, Kanno N et al (2006) Hyper fibrinogenemia is associated with lymphatic as well as hematogenous metastasis and worse clinical outcome in T2 gastric cancer. BMC Cancer 6:147PubMedPubMedCentralCrossRef
51.
Zurück zum Zitat Olterauer S, Grimm C, Seebacher V et al (2009) Plasma fibrinogen levels and prognosis in patients with ovarian cancer: a multicenter study. Oncologist 14:979Y985 Olterauer S, Grimm C, Seebacher V et al (2009) Plasma fibrinogen levels and prognosis in patients with ovarian cancer: a multicenter study. Oncologist 14:979Y985
52.
Zurück zum Zitat Shu YJ, Weng H, Bao RF et al (2014) Clinical and prognostic significance of preoperative plasma hyperfibrinogenemia in gallbladder cancer patients following surgical resection: a retrospective and in vitro study. BMC Cancer 14:566PubMedPubMedCentralCrossRef Shu YJ, Weng H, Bao RF et al (2014) Clinical and prognostic significance of preoperative plasma hyperfibrinogenemia in gallbladder cancer patients following surgical resection: a retrospective and in vitro study. BMC Cancer 14:566PubMedPubMedCentralCrossRef
53.
Zurück zum Zitat Zheng S, Shen J, Jiao Y et al (2009) Platelets and fibrinogen facilitate each other in protecting tumour cells from natural killer cytotoxicity. Cancer Sci 100:859–865PubMedCrossRef Zheng S, Shen J, Jiao Y et al (2009) Platelets and fibrinogen facilitate each other in protecting tumour cells from natural killer cytotoxicity. Cancer Sci 100:859–865PubMedCrossRef
54.
Zurück zum Zitat Steinbrecher KA, Horowitz NA, Blevins EA et al (2010) Colitis-associated cancer is dependent on the interplay between the hemostatic and inflammatory systems and supported by integrin alpha(M)beta(2) engagement of fbrinogen. Cancer Res 70:2634–2643PubMedPubMedCentralCrossRef Steinbrecher KA, Horowitz NA, Blevins EA et al (2010) Colitis-associated cancer is dependent on the interplay between the hemostatic and inflammatory systems and supported by integrin alpha(M)beta(2) engagement of fbrinogen. Cancer Res 70:2634–2643PubMedPubMedCentralCrossRef
Metadaten
Titel
Systemic immune-inflammation index, serum albumin, and fibrinogen impact prognosis in castration-resistant prostate cancer patients treated with first-line docetaxel
verfasst von
Ya-nan Man
Yan-fang Chen
Publikationsdatum
27.08.2019
Verlag
Springer Netherlands
Erschienen in
International Urology and Nephrology / Ausgabe 12/2019
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-019-02265-4

Weitere Artikel der Ausgabe 12/2019

International Urology and Nephrology 12/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.